SCHEDULE 13G: Nemean Asset Management and Steven Oliveira Disclose Significant Passive Stake in Forte Biosciences

Nemean Asset Management, LLC and Steven M. Oliveira have disclosed a 6.76% beneficial ownership stake in Forte Biosciences, Inc., totaling 432,276 shares of common stock.

Summary

• Nemean Asset Management, LLC and Steven M. Oliveira are the reporting persons in this Schedule 13G filing.
• The filing pertains to their beneficial ownership of Common Stock, $0.001 par value, of Forte Biosciences, Inc.
• The CUSIP number for the securities is 34962G208.
• As of November 20, 2024, the reporting persons beneficially own an aggregate of 432,276 shares of Forte Biosciences, Inc. common stock.
• This ownership represents 6.76% of the outstanding class of securities.
• Both Nemean Asset Management, LLC and Steven M. Oliveira hold shared voting power and shared dispositive power over all 432,276 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Forte Biosciences, Inc.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of a significant passive ownership stake, which can be viewed as a vote of confidence by the reporting persons in Forte Biosciences, Inc. It contains no negative information about the company.

Positives

• Nemean Asset Management, LLC and Steven M. Oliveira have acquired a significant 6.76% stake in Forte Biosciences, Inc., indicating a notable investment interest.
• The filing explicitly states that the securities were not acquired for the purpose of changing or influencing the control of the issuer, suggesting a passive investment strategy that may be less disruptive to current management.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Forte Biosciences, Inc.'s future performance or strategic direction, as it is a beneficial ownership disclosure.

Management Comments

• Steven Oliveira, as Authorized Signatory for Nemean Asset Management, LLC, and in his individual capacity, certified that the information set forth in the statement is true, complete, and correct to the best of his knowledge and belief.
• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This Schedule 13G filing is a routine disclosure of a passive investment stake, common in the financial industry when an investor crosses a significant ownership threshold. It does not provide specific insights into broader industry trends or competitive landscape for Forte Biosciences, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a new significant passive investor may be perceived as a positive signal, potentially increasing investor confidence in Forte Biosciences, Inc.
• Company Management: Awareness of a new significant passive investor, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

Keywords

Forte Biosciences, Nemean Asset Management, Steven Oliveira, Schedule 13G, beneficial ownership, common stock, SEC filing, investment